GleamWall
中文EN

ABVX Abivax S.A. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1956827 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-90.7%
TTM EPS YoY-72.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-135.6%
ROA-85.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.1%
Debt / equity0.00x
Current ratio8.75x
Interest coverage-2.15x

Cash quality & payout

Operating cash flow / net income0.48x
Accruals ratio-44.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q1*2025-03-312024Q4*2024-12-312024Q3*2024-09-302024Q2*2024-06-302024Q1*2024-03-31
Income statement
Revenue————————
R&D expense44.40M55.42M38.65M39.30M38.60M43.29M28.91M35.74M
SG&A expense25.87M25.50M8.27M8.03M7.64M7.38M9.80M8.14M
Operating income-71.65M-80.71M-46.50M-47.20M-42.80M-50.19M-35.33M-44.67M
Interest expense9.27M93.05M5.42M6.72M364,0008.47M7.06M4.23M
Pretax income-76.11M-153.36M-48.41M-52.37M-39.38M-55.23M-38.77M-42.87M
Income tax5.85M0000000
Net income-81.96M-153.36M-48.41M-52.37M-39.38M-55.23M-38.77M-42.87M
EBITDA-71.37M-80.44M-46.24M-46.93M-42.52M-49.94M-34.96M-44.46M
EPS (basic)—-2.10-0.76-0.83—-0.87-0.62-0.68
EPS (diluted)—-2.10-0.76-0.83—-0.87-0.62-0.68
Weighted avg. shares (diluted)—72.94M63.44M63.38M—63.23M62.92M62.92M
Balance sheet
Cash & equivalents516.68M589.70M60.95M103.58M144.22M180.45M222.32M241.61M
Short-term investments0000136,000———
Current assets551.24M619.29M86.10M132.67M170.67M———
PP&E, netmay include right-of-use assets (IFRS)2.09M1.91M2.16M2.41M2.67M2.62M2.57M686,000
Goodwill18.42M18.42M18.42M18.42M18.42M———
Intangibles6.61M6.61M6.61M6.61M6.61M6.61M6.61M6.60M
Total assets584.34M652.05M119.64M166.94M205.23M———
Current liabilities63.02M78.76M112.35M105.74M94.00M———
Total liabilities129.14M140.81M167.92M173.53M164.64M———
Shareholders' equity455.20M511.24M-48.28M-6.59M40.58M75.88M126.47M158.87M
Shares outstanding——63.47M63.42M63.35M———
Cash flow statement
Operating cash flow-23.23M-71.28M-33.34M-33.28M-33.51M-35.38M-50.42M-34.75M
Capital expenditure87,000-8,00019,00044,00093,000311,000224,00012,000
Free cash flow-23.32M-71.28M-33.36M-33.32M-33.61M-35.69M-50.65M-34.77M
Investing cash flow-12.74M3.28M187,0001.08M556,0001.75M11.56M1.90M
Financing cash flow-39.55M603.46M-8.77M-7.84M-5.83M-6.29M19.12M21.20M
Depreciation & amortization276,000272,000251,000273,000279,000245,000365,000211,000
Stock-based compensation12.90M11.48M6.33M4.69M4.46M4.35M5.67M5.75M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.